2 Beaten-Down Stocks That Could Bounce Back in 2026

Viking Therapeutics (VKTX) is a clinical-stage biotech advancing VK2735, a GLP‑1 anti-obesity candidate now in phase 3 with an oral formulation; mid‑stage efficacy was strong but high-dose patient dropouts from severe adverse reactions weighed on the stock, and phase‑3 readouts next year could materially re-rate shares. Zoetis (ZTS) suffered 2025 setbacks after reports of severe adverse reactions to Librela and Solensia and ensuing regulatory scrutiny that dented results, but recent approvals of Lenivia (dogs) and Portela (cats) in Europe/Canada for longer‑acting OA pain treatments and a long track record of dividend growth (payouts up ~458% over the past decade) provide potential upside and stability for investors.

Analysis

Market structure: VKTX is a binary-upside winner if Phase‑3 VK2735 readouts (expected within 6–12 months) replicate Phase‑2; success would command premium pricing in the GLP‑1 obesity stack and materially change small‑cap biotech flows. ZTS is a defensive winner over 12–24 months given durable dermatology cash flow and new OA product launches (Lenivia/Portela) but faces near‑term regulatory and demand headwinds that can depress growth by an estimated 1–3 percentage points of top‑line next year.

Risk assessment: Tail risks include VKTX Phase‑3 failure or a safety signal causing >50% downside and regulatory holds, and a Zoetis recall/regulatory sanction that could shave multiple quarters of sales (low probability but high impact). Immediate (days) risk is volatility spikes around headlines, short‑term (weeks–months) risks are regulatory notices and early readouts, long‑term (quarters–years) are market share shifts and pricing pressure; hidden dependencies include manufacturing scale, partner indemnities and reimbursement dynamics in both human and veterinary channels.

Trade implications: Size positions conservatively: treat VKTX as a 2–3% tactical stake via 9–12 month call spreads (cost ≤5% notional) or long calls with a 6‑month put hedge if put premium <2% of notional; rotate capital into ZTS as a 3–5% core holding on a >10% drawdown or on two consecutive quarters of stable OA sales. Use pair trade long ZTS/short VKTX (3% vs 1.5%) to capture rotation out of binary biotech; for income, write 30–90 day covered calls on ZTS 10–15% OTM to monetize elevated vol.

Contrarian angles: The market underestimates salvageable upside for VKTX because adverse events clustered at top doses — dose optimization or reformulation (oral to injectable switch) could restore commercial potential, producing asymmetric returns. Conversely Zoetis may be oversold relative to fundamentals: historical pet‑drug safety scares have seen recovery in 6–18 months once regulatory clarity and alternative product uptake are visible, so avoid knee‑jerk exits and size position for mean reversion.

Key Decisions for Investors

• Establish a tactical long in VKTX equal to 2–3% of equity exposure via 9–12 month call spreads (limit cost to ≤5% of notional). Add a protective 6‑month put if the put premium is <2% of notional; trim position on +100% or on an adverse interim DSMB safety signal.
• Increase exposure to Zoetis (ZTS) to 3–5% of equity allocation on a >10% price pullback or after two sequential quarters showing stabilization of OA product sales; if already long, sell 30–90 day covered calls 10–15% OTM to harvest premium until regulatory clarity (target ~2–4% annualized carry).
• Implement a pair trade: long ZTS (3%) / short VKTX (1.5%) to express rotation from binary biotech risk into cash‑generating animal health; close pair if VKTX rises >50% or ZTS falls >15% from entry, or on definitive Phase‑3 readout/regulatory resolution.
• Monitor specific near‑term catalysts: (1) VKTX Phase‑3 interim/readout window (6–12 months) and DSMB notices within 30–90 days; (2) regulatory communications/recall notices for Librela/Solensia and uptake metrics for Lenivia/Portela in Q1–Q2 2026. Use these as binary triggers to double down or exit positions.